Possible mechanism underlying the efficacy of low dose cyclosporine in autoimmune diseases.
Matsushita
M
M
Takeda-Hirokawa
N
N
Ogasawara
H
H
Sugiyama
M
M
Ando
S
S
Sekigawa
I
I
Iida
N
N
Hashimoto
H
H
Hirose
S
S
D000328:Adult; D016516:CD4-CD8 Ratio / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006684:HLA-DR Antigens / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D019410:Interleukin-16 / Q000097:blood; D008775:Methylprednisolone / Q000627:therapeutic use; D008947:Mixed Connective Tissue Disease / Q000188:drug therapy* / Q000473:pathology
D006684:HLA-DR Antigens; D007166:Immunosuppressive Agents; D019410:Interleukin-16; D016572:Cyclosporine; D003520:Cyclophosphamide; D008775:Methylprednisolone